Currently, the effective refractive surgery for myopia, hyperopia and astigmatism. LASIK is the latest innovation in the correction of vision defects. LASIK is an acronym for laser assisted in situ keratomileusis. Compared to the original PRK laser, the surface of the cornea remains largely intact, so that LASIK patients are able to faster and more convenient to see better.

LASIK is performed internationally known for about 10 years. E ‘first U.S. study in 1991. It is important to note that the main components of the process have a long history. Ophthalmologists have transformed the cornea more than 50 years, creating a protective layer of fabric for more than 35 years, and with the excimer laser since the 1980s.

In 1996, the FDA has responded via the data submitted to and approved laser for the treatment of low myopia up to -6.00 diopters. In 1997, the FDA approved laser for the treatment of astigmatism up to -4.00 diopters. Currently, there are three manufacturers of excimer laser equipment: Summit Technology, VISX and Nidek.

21. October 1999 - Summit Technology, Inc., which granted U.S. Food and Drug Administration (FDA) approval for the company Apex Plus Excimer Laser Workstation for LASIK treatment of myopia with or without astigmatism. The authorization is valid for the correction of myopia between the 0D-to 14.0D with or without astigmatism ranging from 0.5d valid-to-5.0D. This approval allows the widest range of treatments for myopia and astigmatism at the forefront of the industry.

19. November 1999 - VISX, Incorporated (Nasdaq: VISX) announced today that the U.S. Food and Drug Administration (FDA), the use of the VISX STAR S2 Excimer Laser System (TM) as safe and effective for the treatment of up to 14 diopters of myopia, or nearsightedness, with up to 5 diopters astigmatism.

30. September 1999 - Nidek, Inc., had been cleared by the FDA on the PMA supplement provided by EC-5000 Excimer Laser System for the treatment of photorefractive keratectomy for moderate myopia with astigmatism.

The new approval allows the treatment to the reduction or elimination of mild myopia (nearsightedness) and astigmatism (irregular curvature of the cornea). The approval is the correction of myopia ranging from -1.00 to -8.00 diopters of gravity (D), with refractive astigmatism between -0.50 and -4.00 D cylinder by manifest refraction.

March 2000 - The LADARVision excimer laser, which is independent Technologies, Inc., recently approved by the FDA, an order to rectify in his own system of small laser spot nearsightedness, farsightedness and astigmatism. We look forward to this new generation of laser technology to ensure our patients.